FDA advisory panel votes to place popular peptide TB-500 on compounding list

XLV•2026-07-23

FDA panel backs broader compounding for TB-500

July 23 (Reuters) - A panel of advisers to the U.S. Food and Drug Administration on Thursday voted to place a popular peptide called TB-500 on a list that would allow broader pharmacy compounding.

Eight panel members voted in favor, while six voted against. One member abstained.

The FDA is not bound by the panel's recommendations and will ultimately decide whether to loosen restrictions on the peptides.

FDA advisory panel votes to place popular peptide TB-500 on compounding list

FDA panel backs broader compounding for TB-500

Related News

Picpay Receives Final Regulatory Approval For Acquisition Of Kovr

Teamsters US Foods Teamsters Local 507 Unanimously Ratify First Contract With 17% Wage Increase

Thrivent Financial for Lutherans sells USD 28,282 of Gloo Holdings common shares

Icahn Enterprises schedules Q2 earnings webcast

Archrock raises quarterly dividend to $0.23 a share